September 14 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, has added a non-invasive genomic sequencing panel, Tempus xF, a liquid biopsy cell-free DNA assay that analyzes 77 genes, to its sequencing capabilities.. Tempus xF will be run in the company’s state-of-the-art next-generation sequencing lab. The performance of the test has been validated in accordance with CLIA and CAP guidelines.
A liquid biopsy, such as xF, is a non-invasive alternative to tissue-based biopsies which can be used to monitor disease course including response to treatment and resistance mutations. For metastatic disease, liquid biopsies may allow physicians to monitor the course of the disease process by looking for resistance mutations and emerging alterations that may be treatable.
“At Tempus, we believe that understanding patients’ clinical and molecular journey over time is critical to efforts to regularly deliver personalized medicine,” said Gary Palmer, Chief Medical Officer at Tempus. “Tempus xF is a valuable option that can be used as a standalone test or over the course of care with our larger assays to help oncologists and their patients plan treatment or evaluate the effectiveness of treatment over time.”
Tempus has built a series of data pipelines to collect, cleanse, and analyze clinical and molecular data in an effort to usher in precision medicine. Tempus xF joins an existing library of CLIA/CAP validated assays including xE, which analyzes the whole exome; xT, which analyzes 595 genes; and xO, which analyzes 1714 genes. The new Tempus xF assay will help expand the company’s capabilities across both clinical and research initiatives. As with the previous assays, oncologists who order the xF test, will receive a comprehensive report in about two weeks that highlights key findings, including actionable treatments that can be translated into cancer patient care.